Semax: stroke-oriented pharmaceutical composition — RU2251429C2
И.П. Ашмарин (RU), И.П. Ашмарин, Л.Ю. Алфеева (RU), Л.Ю. Алфеева, Л.А. Андреева (RU), Л.А. Андреева, И.А. Гривенников (RU), И.А. Гривенников, Е.И. Гусев (RU), Е.И. Гусев, О.В. Долотов (RU), О.В. Долотов, А.А. Каменский (RU), А.А. Каменский, соедов Н.Ф. М (RU), Н.Ф. Мясоедов, В.Н. Незавибатько (RU), В.Н. Незавибатько, А.В. Немерский (RU), А.В. Немерский, В.И. Скворцова (RU), В.И. Скворцова · 2005 · RU2251429C2 · patent family 35747098
Published 2005-05-10.
Reported patent results
Reported findings
The patent reports faster neurological regression, with incompletely specified subgroup percentage denominators.
Patent stroke comparison: 80 patients, 40 Semax-formulation and 40 control; severity mix differed (24 versus 20 moderate cases).
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Moderate-stroke course | Regression reported in 88% with Semax versus 55.2% control | Percentages retained as printed; subgroup denominators do not map cleanly to these values |
| Moderate-stroke functional recovery | 80% reported good recovery and 36% complete focal-symptom regression | Patent narrative; no prespecified modern functional endpoint established · End of acute period |
Allocation, masking, subgroup denominators and concurrent care require original-trial verification. This patent may reproduce clinical material already in the literature and is not an additional independent trial.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The patent concerns a Semax formulation proposed for stroke-related applications.
A formulation filing is not a newly completed stroke trial or proof of healthy-person cognitive enhancement.
- Publication
- RU2251429C2 ↗ · 2005-05-10
- Earliest priority / filing
- 2002-12-30 / 2002-12-30
- Original applicant / assignee
- Институт Молекулярной Генетики Российской Академии Наук (Имг Ран)
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 35747098 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition for treating ischemic insult and method for therapy
Inventors: И.П. Ашмарин (RU); И.П. Ашмарин; Л.Ю. Алфеева (RU); Л.Ю. Алфеева; Л.А. Андреева (RU); Л.А. Андреева; И.А. Гривенников (RU); И.А. Гривенников; Е.И. Гусев (RU); Е.И. Гусев; О.В. Долотов (RU); О.В. Долотов; А.А. Каменский (RU); А.А. Каменский; соедов Н.Ф. М (RU); Н.Ф. Мясоедов; В.Н. Незавибатько (RU); В.Н. Незавибатько; А.В. Немерский (RU); А.В. Немерский; В.И. Скворцова (RU); В.И. Скворцова.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A formulation filing is not a newly completed stroke trial or proof of healthy-person cognitive enhancement.
- Allocation, masking, subgroup denominators and concurrent care require original-trial verification. This patent may reproduce clinical material already in the literature and is not an additional independent trial.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-35747098. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: И.П. Ашмарин (RU), И.П. Ашмарин, Л.Ю. Алфеева (RU), Л.Ю. Алфеева, Л.А. Андреева (RU), Л.А. Андреева, И.А. Гривенников (RU), И.А. Гривенников, Е.И. Гусев (RU), Е.И. Гусев, О.В. Долотов (RU), О.В. Долотов, А.А. Каменский (RU), А.А. Каменский, соедов Н.Ф. М (RU), Н.Ф. Мясоедов, В.Н. Незавибатько (RU), В.Н. Незавибатько, А.В. Немерский (RU), А.В. Немерский, В.И. Скворцова (RU), В.И. Скворцова. Semax: stroke-oriented pharmaceutical composition — RU2251429C2 RU2251429C2 · patent family 35747098 2005.
Molekul research summary: https://molekul.io/research/patent-ru2251429c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry